KromaTiD Announces Third U.S. Patent and New Proprietary Capabilities

Fort Collins, Colorado September 21, 2015:  With the issuance of its third U.S. patent (#9,090,935 B2), KromaTiD is pleased to announce an expansion of its full genome screening platform to include a new set of unique methods for understanding the structure of novel disease causing mutations.

Read more

KromaTiD Chosen to Present at 2015 Rocky Mountain Life Science Investor and Partnering Conference

Fort Collins, Colorado – September 16, 2015:  KromaTiD, Inc. joins 29 other innovative life science companies from the Rocky Mountain region chosen to present at the 2015 Rocky Mountain Life Science Investor and Partnering Conference (RMLIPC). Representing Arizona, Colorado, Montana, New Mexico and Utah, the companies include emerging and established companies offering groundbreaking pharmaceuticals, medical devices, therapies and technologies.

Read more